免疫原性死亡的增效策略及其纳米 技术研究进展
Synergistic Strategies for Immunogenic Cell Death and Recent Advances in Nanotechnology Research
DOI: 10.12677/acm.2026.1641401, PDF,   
作者: 梅露凡, 王 桔：昆明医科大学药学院云南省天然药物药理重点实验室，云南 昆明；姜文笔, 田子豪：昆明医科大学康复学院云南省干细胞和再生医学重点实验室，云南 昆明；李 璠*：昆明医科大学科技成果转化中心，云南 昆明
关键词: 免疫原性细胞死亡；纳米药物递送系统；损伤相关分子模式；肿瘤免疫微环境；化学免疫治疗；Immunogenic Cell Death； Nanoparticle Drug Delivery Systems； Damage-Associated Molecular Patterns； Tumor Immune Microenvironment； Chemoimmunotherapy
摘要: 免疫原性细胞死亡是连接传统肿瘤治疗与免疫应答的关键桥梁，但传统化疗或放疗诱导的免疫原性细胞死亡效率低下且免疫转化不充分，严重制约了抗肿瘤免疫疗效。纳米技术通过精准递送、多药协同及微环境重塑等策略，显著提高免疫原性细胞死亡的质量，已成为肿瘤免疫治疗领域的研究前沿。本文系统概述了免疫原性细胞死亡增效纳米系统的多维作用机制、材料设计策略及评价方法，分析了当前面临的机制争议与转化挑战，并展望了时序控释、逻辑门控及与细胞疗法融合等未来发展方向，为下一代肿瘤纳米免疫治疗药物的研发提供理论参考。
Abstract: Immunogenic cell death (ICD) serves as a critical bridge connecting conventional tumor therapies with immune responses. However, the immunotherapeutic efficacy against tumors is severely limited by the inefficient ICD induction and insufficient immunological conversion mediated by traditional chemotherapy or radiotherapy. Nanotechnology has emerged as a research frontier in tumor immunotherapy by significantly enhancing both the quality and quantity of ICD through strategies such as precision delivery, multidrug synergy, and microenvironment remodeling. This review systematically discusses the multidimensional mechanisms, material design strategies, and evaluation methods of ICD-enhancing nanosystems. It further analyzes current mechanistic controversies and translational challenges, while prospecting future directions including temporally controlled release, logic-gated regulation, and integration with cell therapies, thereby providing theoretical references for the development of next-generation nano-based cancer immunotherapeutics.
文章引用：梅露凡, 王桔, 姜文笔, 田子豪, 李璠. 免疫原性死亡的增效策略及其纳米 技术研究进展[J]. 临床医学进展, 2026, 16(4): 1637-1647. https://doi.org/10.12677/acm.2026.1641401

参考文献

[1] Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L. and Kroemer, G. (2017) Immunogenic Cell Death in Cancer and Infectious Disease. Nature Reviews Immunology, 17, 97-111. [Google Scholar] [CrossRef] [PubMed]
[2] Garg,, A.D., Galluzzi, L., Apetoh, L., et al. (2015) Molecular and Translational Classifications of Damps in Immunogenic Cell Death. Frontiers in Immunology, 6, Article 588.
[3] Shi, J., Kantoff, P.W., Wooster, R. and Farokhzad, O.C. (2017) Cancer Nanomedicine: Progress, Challenges and Opportunities. Nature Reviews Cancer, 17, 20-37. [Google Scholar] [CrossRef] [PubMed]
[4] Engelen, Y., Demuynck, R., Ramon, J., Breckpot, K., De Smedt, S.C., Lajoinie, G.P.R., et al. (2025) Immunogenic Cell Death as Interplay between Physical Anticancer Modalities and Immunotherapy. Journal of Controlled Release, 384, Article 113721. [Google Scholar] [CrossRef] [PubMed]
[5] Chen, X., Chen, C., Zhang, Y., Gong, T., Zhang, Z., Zhang, L., et al. (2026) Activating Antigen-Specific T Cells by the Dual Action of Paclitaxel to Enhance Tumor Immunotherapy. European Journal of Pharmaceutical Sciences, 219, Article 107476. [Google Scholar] [CrossRef] 
[6] Deng, X., Zhang, Z., Ren, T. and Chen, L. (2025) Regulation of Oxidative Stress and Inflammation Caused by Drug Accumulation in the TME Based on EPR-Passive Strategy and Active Targeting. Cancer Nanotechnology, 16, Article No. 40. [Google Scholar] [CrossRef] 
[7] Singh, D. and Kumar, A. (2025) Next-Generation Nanocarriers for Precision Antitumor Therapy: From Passive Targeting to Intelligent Response. Exploration of Targeted Anti-Tumor Therapy, 6, Article 1002355. [Google Scholar] [CrossRef] 
[8] Choi, M., Shin, J., Lee, C., Chung, J., Kim, M., Yan, X., et al. (2023) Immunogenic Cell Death in Cancer Immunotherapy. BMB Reports, 56, 275-286. [Google Scholar] [CrossRef] [PubMed]
[9] Duan, X., Chan, C. and Lin, W. (2019) Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. Angewandte Chemie International Edition, 58, 670-680. [Google Scholar] [CrossRef] [PubMed]
[10] Hiep Tran, T. and Thu Phuong Tran, T. (2024) Current Status of Nanoparticle-Mediated Immunogenic Cell Death in Cancer Immunotherapy. International Immunopharmacology, 142, Article 113085. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, H., Li, S., Liu, S., Liao, Y., Liu, H., Yang, M., et al. (2025) Therapeutic Targeting of Cell Death-Immune Crosstalk in Cancer to Rewire the Tumor Immune Microenvironment. Molecular Cancer, 24, Article No. 277. [Google Scholar] [CrossRef] 
[12] Huang, Z., Wang, Y., Yao, D., Wu, J., Hu, Y. and Yuan, A. (2021) Nanoscale Coordination Polymers Induce Immunogenic Cell Death by Amplifying Radiation Therapy Mediated Oxidative Stress. Nature Communications, 12, Article No. 145. [Google Scholar] [CrossRef] [PubMed]
[13] Zhang, Q., Lin, L., Chen, G., Nie, M., Chen, G., Tang, Y., et al. (2026) Disrupting Tumor Homeostasis with an Autoamplificatory Nanoinducer to Augment Pyroptosis for Efficient Immunotherapy. Biomaterials, 324, Article 123544. [Google Scholar] [CrossRef] [PubMed]
[14] Duan, Q.Y., Wang, L., Cheng, X., Qiu, S., et al. (2026) Highly Active Strontium Peroxide Nanoparticles Induce Alkalization/Oxidation to Potentiate Cancer Immuno-Metabolic Therapy. ACS Nano, 20, 3030-3047. [Google Scholar] [CrossRef] 
[15] Banstola, A., Poudel, K., Kim, J.O., Jeong, J. and Yook, S. (2021) Recent Progress in Stimuli-Responsive Nanosystems for Inducing Immunogenic Cell Death. Journal of Controlled Release, 337, 505-520. [Google Scholar] [CrossRef] [PubMed]
[16] Higgs, E.F. and Gajewski, T.F. (2024) Synergistic Innate Immune Activation and Anti-Tumor Immunity through Combined Sting and Tlr4 Stimulation.
[17] Song, H., Chen, L., Pan, X., Shen, Y., Ye, M., Wang, G., et al. (2025) Targeting Tumor Monocyte-Intrinsic PD-L1 by Rewiring STING Signaling and Enhancing STING agonist Therapy. Cancer Cell, 43, 503-518.e10. [Google Scholar] [CrossRef] [PubMed]
[18] Attia, M.F., Anton, N., Wallyn, J., Omran, Z. and Vandamme, T.F. (2019) An Overview of Active and Passive Targeting Strategies to Improve the Nanocarriers Efficiency to Tumour Sites. Journal of Pharmacy and Pharmacology, 71, 1185-1198. [Google Scholar] [CrossRef] [PubMed]
[19] Liu, W., Jing, Y., Chen, Y., Sun, H., Xu, W., Liang, R., et al. (2025) Research Progress on the Cross-Regulation between Ferroptosis and Immunogenic Cell Death in Tumor Micro-Environment. Frontiers in Oncology, 15, Article 1581951. [Google Scholar] [CrossRef] [PubMed]
[20] Guo, G., Ding, W., Li, F., Li, Z., Qin, S., Xu, G., et al. (2025) Nano Co-Inducer of Immunogenic Cell Death and Ferroptosis for Anti-Tumor Immunotherapy. Journal of Colloid and Interface Science, 697, Article 137980. [Google Scholar] [CrossRef] [PubMed]
[21] Deng, X.C., Liang, J.L., Zhang, S.M., et al. (2024) Interference of Atp‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor Immunotherapy. Advanced Materials, 36, e2405673. [Google Scholar] [CrossRef] [PubMed]
[22] Jiao, W., Feng, Y., Liang, C., Lu, Q., Fan, H., Liang, X., et al. (2023) Reprogramming the Tumor Immune Microenvironment via Nanomaterial-Mediated Dynamic Therapy. Nano Research, 16, 13100-13112. [Google Scholar] [CrossRef] 
[23] Pandey, S., Joshi, S., Tripathi, P., Gupta, A. and Yadav, J.S. (2025) A Review on Targeting Tunable Nanocarrier Interaction, Physiochemical Properties, and Futuristic Nanocarrier. Biochimica et Biophysica Acta—Molecular Basis of Disease, 1871, Article 167956. [Google Scholar] [CrossRef] [PubMed]
[24] Hou, P., Tang, C., Zhao, W. and Li, Z. (2025) Preparation and Characterization of Polysaccharide-Derived Smart Nanocarriers for Stimuli-Responsive Delivery of Natural Extracts in NSCLC Therapy. Carbohydrate Research, 558, Article 109670. [Google Scholar] [CrossRef] 
[25] Xiang, W., He, S., Zheng, Z., Liu, Y., Liu, X., Kuang, T., et al. (2025) A Self-Adaptive Rhodium(I) Complex-Based Nanoplatform with Type II Immunogenic Cell Death for Near-Infrared Phosphorescence Imaging and Cancer Immunotherapy. Advanced Healthcare Materials, 14, e01871. [Google Scholar] [CrossRef] [PubMed]
[26] Kong, M. and Qiu, L. (2025) Coordinated Modulation of Glucose Metabolism and Immunity via Metal-Drug Nanovesicles for Hepatocellular Carcinoma Therapy. Journal of Controlled Release, 384, Article 113957. [Google Scholar] [CrossRef] [PubMed]
[27] Peng, Y., Yu, M., Li, B., Zhang, S., Cheng, J., Wu, F., et al. (2025) Advances in Nanocarrier-Mediated Cancer Therapy: Progress in Immunotherapy, Chemotherapy, and Radiotherapy. Chinese Medical Journal, 138, 1927-1944. [Google Scholar] [CrossRef] [PubMed]
[28] Tian, M., Xin, X., Wu, R., Guan, W. and Zhou, W. (2022) Advances in Intelligent-Responsive Nanocarriers for Cancer Therapy. Pharmacological Research, 178, Article 106184. [Google Scholar] [CrossRef] [PubMed]
[29] Yang, W., Yi, J., Zhu, R., Guo, Y., Zhang, K., Cao, Y., et al. (2023) Transformable Prodrug Nanoplatform via Tumor Microenvironment Modulation and Immune Checkpoint Blockade Potentiates Immunogenic Cell Death Mediated Cancer Immunotherapy. Theranostics, 13, 1906-1920. [Google Scholar] [CrossRef] [PubMed]
[30] Du, M., Wang, T., Peng, W., Feng, R., Goh, M. and Chen, Z. (2024) Bacteria-driven Nanosonosensitizer Delivery System for Enhanced Breast Cancer Treatment through Sonodynamic Therapy-Induced Immunogenic Cell Death. Journal of Nanobiotechnology, 22, Article No. 167. [Google Scholar] [CrossRef] [PubMed]
[31] Mohamed, R.G.A., Ali, S.M., Ahmed, I.S., Rawas-Qalaji, M. and Hussain, Z. (2025) Next-Generation Nanocarriers for Colorectal Cancer: Passive, Active, and Stimuli-Responsive Strategies for Precision Therapy. Biomaterials Science, 13, 5626-5664. [Google Scholar] [CrossRef] 
[32] Feng, J., He, D., Chen, J., Li, M., Luo, J., Han, Y., et al. (2025) Cell Membrane Biomimetic Nanoplatforms: A New Strategy for Immune Escape and Precision Targeted Therapy. Materials Today Bio, 35, Article 102343. [Google Scholar] [CrossRef] 
[33] Erdei, E., Deme, R., Balogh, B. and Mándity, I.M. (2025) Cell-Mediated and Peptide-Based Delivery Systems: Emerging Frontiers in Targeted Therapeutics. Pharmaceutics, 17, Article 1597. [Google Scholar] [CrossRef] 
[34] Xie, D., Dong, Y., He, Z., Sun, J. and Sun, M. (2025) Artificial Intelligence-Designing Drug-Loaded Bacterial Outer Membrane Vesicles for in Vitro Activation of Dendritic Cells. Acta Pharmaceutica Sinica, 60, 1525-1533.
[35] Sun, S., He, Y., Xu, J., Leng, S., Liu, Y., Wan, H., et al. (2024) Enhancing Cell Pyroptosis with Biomimetic Nanoparticles for Melanoma Chemo-Immunotherapy. Journal of Controlled Release, 367, 470-485. [Google Scholar] [CrossRef] [PubMed]
[36] Carmona-Ribeiro, A. (2010) Biomimetic Nanoparticles: Preparation, Characterization and Biomedical Applications. International Journal of Nanomedicine, 5, 249-259. [Google Scholar] [CrossRef] [PubMed]
[37] Chen, Y., Wang, L., Chen, N. and Tang, G. (2024) Metformin Induces Tumor Immunogenic Cell Death in Ovarian Cancer by Activating AMPK Pathway. Translational Oncology, 47, Article 102052. [Google Scholar] [CrossRef] [PubMed]
[38] Jiang, Z., Maggs, L., Zhou, K., Zou, C., Huang, J., Wang, X., et al. (2025) Piperlongumine Enhances the Antitumor Efficacy of PD-1 Inhibitors by Inducing Immunogenic Cell Death in Prostate Cancer Cells. World Journal of Urology, 43, Article No. 406. [Google Scholar] [CrossRef] [PubMed]
[39] Naessens, F., Efimova, I., Saviuk, M. and Krysko, D.V. (2024) Cytofluorometric Analysis of the Maturation and Activation of Bone Marrow-Derived Dendritic Cells to Assess Immunogenic Cell Death. Methods In Cell Biology, 190, 51-74.
[40] Lisandrelli, R., Winkler, M., Trajanoski, Z. and Lamberti, G. (2025) Studying Immunogenic Cell Death in Human Colorectal Cancer Organoids. OncoTargets and Therapy, 18, 705-715. [Google Scholar] [CrossRef] [PubMed]
[41] Jeong, Y.S., Lee, K.J., Kim, Y.J., Lee, S.J., Koom, W.S., Lee, I.J., et al. (2025) Investigating Tumor Immunogenicity as a Determinant of Differential Abscopal Effects. Journal of Radiation Research, 66, 253-263. [Google Scholar] [CrossRef] [PubMed]
[42] Zhong, Y.S., Xie, W., Li, X.J., Ying, H.Z., et al. (2025) Humanized Immune Mouse Models: Emerging Applications for Cancer Immunotherapy. Endocrine, Metabolic & Immune Disorders—Drug Targets, 25, e18715303382108. [Google Scholar] [CrossRef] 
[43] Scheck, J.G., Boztepe, B., Kernbach, J.M., Karimian-Jazi, K., Heinz, L., Schregel, K., et al. (2025) Multimodality Mapping of Immunotherapy Distribution as a Predictive Marker in Glioma. Neuro-Oncology, 2025, noaf295. [Google Scholar] [CrossRef] 
[44] Zhang, L.L., Zhang, D.J., Shi, J.X., et al. (2024) Immunogenic Cell Death Inducers for Cancer Therapy: An Emerging Focus on Natural Products. Phytomedicine, 132, Article 155828. [Google Scholar] [CrossRef] [PubMed]
[45] Catenacci, L., Rossi, R., Sechi, F., Buonocore, D., Sorrenti, M., Perteghella, S., et al. (2024) Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System. Pharmaceutics, 16, Article 1521. [Google Scholar] [CrossRef] [PubMed]
[46] de Souza Cardoso Delfino, C., de Paula Pereira, M.C., dos Santos Oliveira, M., de Carvalho Favareto, I., Valladão, V.S., de Oliveira Mota, M., et al. (2025) Scaling Nanopharmaceutical Production for Personalized Medicine: Challenges and Strategies. Journal of Nanoparticle Research, 27, Article No. 108. [Google Scholar] [CrossRef] 
[47] Li, Y., Li, X., Zhang, M., Weng, X., Yi, J., Cao, Y., et al. (2024) Spatiotemporal Orchestration of a Ferroptosis-Immunotherapy “Cycle” via a Sequential Drug Delivery System for Antitumor Immunity. Nano Today, 59, Article 102535. [Google Scholar] [CrossRef] 
[48] Wang, Q., Chang, R., Li, X., Zhang, Y., Fan, X., Shi, L., et al. (2025) Logic-Gated DNA Intelligent Nanorobots for Cellular Lysosome Interference and Enhanced Therapeutics. Angewandte Chemie International Edition, 64, e202423004. [Google Scholar] [CrossRef] [PubMed]
[49] Zuo, M., Wang, J., Zhang, W., Xiao, L., Qiao, Z., Li, W., et al. (2026) Nano-/Nanobio-Technology-Enhanced CAR-T Cell Therapy: Engineering the Next Generation of Immunotherapies. Coordination Chemistry Reviews, 550, Article 217388. [Google Scholar] [CrossRef] 
[50] Huang, G., He, Y., Chen, X., Yin, T., Ma, A., Zhu, L., et al. (2025) Bioorthogonal Oncolytic-Virus Nanovesicles Combined Bio-Immunotherapy with CAR-T Cells for Solid Tumors. Biomaterials Science, 13, 457-465. [Google Scholar] [CrossRef] [PubMed]
[51] Li, Z., Fu, C., Chen, J., Ji, W. and Ma, Z. (2025) Identification and Validation of an Immune-Related Programmed Cell Death Signature for Predicting Prognosis and Immunotherapy in Large-Scale Multicenter Cohorts for Lung Adenocarcinoma. Translational Cancer Research, 14, 6152-6171. [Google Scholar] [CrossRef] 
[52] Holtermann, A., Gislon, M., Angele, M., Subklewe, M., von Bergwelt-Baildon, M., Lauber, K., et al. (2024) Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs, 38, 611-637. [Google Scholar] [CrossRef] [PubMed]
[53] Souto, E.B., Blanco-Llamero, C., Krambeck, K., Kiran, N.S., Yashaswini, C., Postwala, H., et al. (2024) Regulatory Insights into Nanomedicine and Gene Vaccine Innovation: Safety Assessment, Challenges, and Regulatory Perspectives. Acta Biomater, 180, 1-17. [Google Scholar] [CrossRef] [PubMed]

为你推荐